NVCR News and Press, NovoCure Limited From 04/11/22

Investing in biotechnology companies is both difficult and incredibly exciting. Watching as a company goes through the regulatory approval process, from a fledgling early-stage clinical trial biotech to an industry juggernaut, can be exhilarating. While positive outcomes aren't guarante...

The following slide deck was published by NovoCure Limited in conjunction with this event. For further details see: NovoCure (NVCR) Investor Presentation - Slideshow

Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in New Orleans from April 8 to April 13, 2022. The research described in the presentation...

With its novel Tumor Treating Fields therapy that uses electrical pulses to treat cancer, Novocure (NASDAQ: NVCR) could offer new hope to patients and physicians. In this Motley Fool Live segment from The Pharma & Biotech Show, recorded on March 23 , Fool.com contributor...

One group stands out as an interesting and potentially dramatically undervalued area of the market in the wake of the pandemic and its historical footprint: Medical device stocks. The healthcare system has been forever changed by the pandemic, which accelerated several core healthcare industr...

Biotech stocks, in general, again performed dismally in the first quarter of 2022. However, there are some signs of improvement. The lower valuations could present a great buying opportunity once the inevitable strong rebound materializes. We asked three Motley Fool contributors which b...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2022 on Thursday, April 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Novocure (NASDAQ: NVCR) could either be a big win or a deep dip for investors. In this clip from "3 Minute Stocks Updates" on Motley Fool Live , recorded on March 2 , Motley Fool contributor Brian Feroldi discusses the reasons why this medical device stock could go either wa...

Patients in phase 2 pilot trial 2-THE-TOP had median progression-free survival of 12.1 months compared with 7.9 months for matched-control patients from EF-14 Novocure (NASDAQ: NVCR) today announced that Dr. David Tran, Chief of the Division of Neuro-Oncology at the McKnight...

An independent data monitoring has recommended that a phase 3 trial of Novocure's (NASDAQ:NVCR) Tumor Treating Fields (TTFs) for ovarian cancer should continue following an interim analysis. The analysis showed that an increase in sample size is not necessary and the committee recommended tha...